Diabetic Macular Edema
Conditions
Interventions
Group A:Intravitreal injection of anti VEGF (0.5mg ranibizumab) only per month
Group B:Intravitreal injection of anti VEGF (0.5mg ranibizumab) and calcium dobesilate (1500 mg / D)
Sponsors
The Fourth Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. type 1 or type 2 diabetes; 3. Participants must meet the following criteria: Best corrected visual acuity ETDRS letter score = 24 (approximate Snellen equivalent between 20 / 32 and 20 / 320) DME with central involvement detected by fundus examination: macular fovea retinal thickness (µ m) was examined by optical coherence tomography (OCT): Zeiss: female >= 290um; male >= 305 um; Heidelberg: female >= 305 um; male >= 320 um. 4. There was no history of DME or Dr laser therapy or drug injection.
Exclusion criteria
Exclusion criteria: 1. Any treatment for proliferative diabetic retinopathy or diabetic macular edema, such as intravitreal injection of anti VEGF drugs or PrP treatment; 2. Cataracts or other opacities that interfere with fundus examination or obtaining high-quality fundus photographs; 3. Other retinal diseases that may affect central vision; 4. Glaucoma that cannot be controlled with only one topical drug; 5. Other research drugs are being used (e.g., participating in another medical study); 6. Pregnancy; lactation; taking contraceptives; 7. They are known to be allergic to calcium dobesilate or similar drugs; they have participated in clinical studies of calcium dobesilate similar drugs; 8. Suffering from any life-threatening illness that may hinder the follow-up of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in mean best corrected visual acuity;Differences in mean CSF thickness; | — |
Countries
China
Contacts
Public ContactKong Jun
The Fourth Affiliated Hospital of China Medical University
Outcome results
None listed